Discussion
The pathogenesis of venous and arterial thrombosis may be different, however, both thrombosis may occur in any given patient with a thrombophilic state. Thrombophilic state is defined trough hypercoagulable state, that refers only to changes in blood coagulation, and trough changes in vessel walls or blood flow as well. Vessel wall changes play an important role in both arterial and venous thrombosis.
Arterial thrombosis occurs mainly due to the erosion or rupture of an atherosclerotic plaque and arterial thrombi are mainly constituted by platelets. Venous changes, such as those created by valve destruction and varicosities, often play a role in the pathogenesis of thrombosis. But combination of stasis and hypercoagulability, much more then endothelial damage itself, is crutial for the development od venous thrombosis. In comparison to arterial thrombi, venous thrombi are mainly constituted by fibrin and red blood cells and less by platelets.
Thrombophilia has both acquired and inherited causes. Tests for heritable thrombophilia should be considered for patients with higher risk of venous and arterial thromboembolic events. Inherited thrombophilia refers to inherited deficiencies of natural inhibitors and inherited mutations of coagulation factors. Inherited protein C and S and antithrombin deficiencies are strong risk factors for venous thrombosis with little effect on arterial thrombosis. The most common inherited risk factor for venous thrombosis is mutation for factor V gene (factor V Leiden) and mutation in the prothrombin gene. The prevalence of these mutations in general population is in the range 3-6%, and in patients with venous thrombosis reaches 21%
1 . Antiphospholipid antibody syndrome is one of the most important acquired risk factors for both, arterial and venous thrombosis. Lupus anticoagulant, an- The metabolic syndrome is also considered to be the risk factor for both, arterial and venous thrombosis 2, 3 . According to the definition proposed in 2001 by the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III), a person is considered to have the metabolic syndrome if he or she has at least three of the following risk factors: overweight or obesity, glucose intolerance, hypertension, high level of triglycerides and/ or low level of high-density lipoprotein (HDL) cholesterol 4 . On the other hand, the American Diabetes Association (ADA) promotes using the term "cardiometabolic risk" since there are other factors which greatly increase the risk for cardiovascular disease, both nonmodifable (age,sex, family hystory) and modifable (hypercoagulation, smoking, inflammation, absence of physical activity). The metabolic syndrom itself is often accompanied by a prothrombotic state including increased plasma levels of factor VII, VIII, fibrinogen, and with increased levels of PAI-1, the latter leading to a hypofibrinolytic state 5, 6 . The increased level of fibrinogen is associated with chronic inflammation and insulin resistance, both present in metabolic syndrom. On the other hand, insulin resistance and chronic inflammation contribute to the increase in PAI-1, the major inhibitor of fibrinolysis, as well.
The fibrinolytic system and its relation to AF with associated underlying mechanisms are not completely understood. Previous studies have shown the role of inflammation, endothelial damage, and fibrinolysis with the confounders such as hypertension or insulin resistance in the development of AF 7 . The PAI-1 level was considered as an independent predictor for AF after coronary artery bypass surgery 8 and the data suggest the PAI-1 levels to be predictive of a successful cardioversion 9 . But recent data from PREVEND study failed to determine the association of PAI-1 and TPA (Tissue-type plasminogen activator) levels with incident AF
10
.
Conclusion
In the patient with the combination of two weak thrombophilias, heterozygotes for plasminogen-activator inhibitor-1 (PAI-1) gene polymorphism as well the MTHFR gene mutation, in the context of metabolic syndrome and classical risk factors could reveal life threatening thromboembolism.
